BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 17446843)

  • 1. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic value of serum CEACAM1 in patients with pancreatic cancer].
    Gong DY; Fu HX; Peng Y; You YQ; Li ZP
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):164-6. PubMed ID: 21269981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
    Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
    Koopmann J; Fedarko NS; Jain A; Maitra A; Iacobuzio-Donahue C; Rahman A; Hruban RH; Yeo CJ; Goggins M
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):487-91. PubMed ID: 15006928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
    Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
    Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses.
    Mataki Y; Takao S; Maemura K; Mori S; Shinchi H; Natsugoe S; Aikou T
    Clin Cancer Res; 2004 Jun; 10(11):3807-14. PubMed ID: 15173089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.
    Rosty C; Christa L; Kuzdzal S; Baldwin WM; Zahurak ML; Carnot F; Chan DW; Canto M; Lillemoe KD; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Cancer Res; 2002 Mar; 62(6):1868-75. PubMed ID: 11912167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.